Adequate Lymph Node Assessments and Investigation of Gut Microorganisms and Microbial Metabolites in Colorectal Cancer

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2020 Mar 19

PMID 32184624

Citations 7

Authors

Shuwen Han

Wei Wu

Miao Da

Jiamin Xu

Jing Zhuang

Longqi Zhang

Xiaoxiang Zhang

Xi Yang

Affiliations

Soon will be listed here.

Abstract

Purpose: To analyze the lymph node metastasis status and prognosis in CRCs and to investigate the gut microorganisms and microbial metabolites at different lymph node stages.

Methods: The Surveillance, Epidemiology, and End Results (SEER) database and STAT software were used to analyze the clinical features and lymph node metastasis. Bacterial 16S V3-V4 and fungal ITS V3-V4 ribosomal RNA genes were sequenced in 53 stool samples and gas chromatography/mass spectrometry (GS/MS) was performed to detect the microbial metabolites in 48 stool samples from CRC patients.

Results: A higher number of lymph node metastases predicted a poor prognosis. Inadequate evaluation of lymph nodes affects the accuracy of prognostic assessments. We constructed a nomogram model for the assessment of prognostic factors. There were multiple characteristic bacteria identified, including , etc., and fungi, including , etc. A total of 27 characteristic microbial metabolites in different lymph node metastasis status were also identified.

Conclusion: Gut microorganisms and microbial metabolites may provide reference and guidance for the adequate lymph node assessments (ALNA) in CRC.

Citing Articles

Intestinal microbiota as biomarkers for different colorectal lesions based on colorectal cancer screening participants in community.

Li G, Zhao D, Ouyang B, Chen Y, Zhao Y Front Microbiol. 2025; 16:1529858.

PMID: 39990152 PMC: 11844352. DOI: 10.3389/fmicb.2025.1529858.

Nomogram for predicting occurrence and prognosis of liver metastasis in elderly colorectal cancer patients: a population-based study.

Wang Q, Shen K, Fei B, Wei M, Xie Z Front Oncol. 2024; 13:1295650.

PMID: 38239646 PMC: 10794770. DOI: 10.3389/fonc.2023.1295650.

TCM syndrome differentiation in colorectal cancer patients assisted by differences in gut microbiota: An exploratory study.

Ming-Bin G, Ya-Nan W, Yong-Ting X, Min Z, Hao T, Lian-Ping Q Heliyon. 2023; 9(11):e21057.

PMID: 37928040 PMC: 10623286. DOI: 10.1016/j.heliyon.2023.e21057.

Rational consideration of Akkermansia muciniphila targeting intestinal health: advantages and challenges.

Luo Y, Lan C, Li H, Ouyang Q, Kong F, Wu A NPJ Biofilms Microbiomes. 2022; 8(1):81.

PMID: 36253412 PMC: 9576740. DOI: 10.1038/s41522-022-00338-4.

Altered Pattern of Immunoglobulin A-Targeted Microbiota in Inflammatory Bowel Disease After Fecal Transplantation.

Huang W, Huang H, Peng W, Liu Y, Zhou Y, Xu H Front Microbiol. 2022; 13:873018.

PMID: 35814647 PMC: 9257281. DOI: 10.3389/fmicb.2022.873018.

References

Shia J, Wang H, Nash G, Klimstra D . Lymph node staging in colorectal cancer: revisiting the benchmark of at least 12 lymph nodes in R0 resection. J Am Coll Surg. 2012; 214(3):348-55. DOI: 10.1016/j.jamcollsurg.2011.11.010. View

Ajani J, DAmico T, Almhanna K, Bentrem D, Chao J, Das P . Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016; 14(10):1286-1312. DOI: 10.6004/jnccn.2016.0137. View

Heinemann V, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S . FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15(10):1065-75. DOI: 10.1016/S1470-2045(14)70330-4. View

Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M . Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018; 103:356-387. DOI: 10.1016/j.ejca.2018.07.005. View

Lucas C, Barnich N, Nguyen H . Microbiota, Inflammation and Colorectal Cancer. Int J Mol Sci. 2017; 18(6). PMC: 5486131. DOI: 10.3390/ijms18061310. View

Calvert P, Frucht H . The genetics of colorectal cancer. Ann Intern Med. 2002; 137(7):603-12. DOI: 10.7326/0003-4819-137-7-200210010-00012. View

Tournigand C, Andre T, Bonnetain F, Chibaudel B, Lledo G, Hickish T . Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the.... J Clin Oncol. 2012; 30(27):3353-60. DOI: 10.1200/JCO.2012.42.5645. View

Ma H, Yu Y, Wang M, Li Z, Xu H, Tian C . Correlation between microbes and colorectal cancer: tumor apoptosis is induced by sitosterols through promoting gut microbiota to produce short-chain fatty acids. Apoptosis. 2018; 24(1-2):168-183. DOI: 10.1007/s10495-018-1500-9. View

Feng Q, Chen W, Wang Y . Gut Microbiota: An Integral Moderator in Health and Disease. Front Microbiol. 2018; 9:151. PMC: 5826318. DOI: 10.3389/fmicb.2018.00151. View

10.

Louis P, Hold G, Flint H . The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. 2014; 12(10):661-72. DOI: 10.1038/nrmicro3344. View

11.

OKeefe S . Diet, microorganisms and their metabolites, and colon cancer. Nat Rev Gastroenterol Hepatol. 2016; 13(12):691-706. PMC: 6312102. DOI: 10.1038/nrgastro.2016.165. View

12.

Wang X, Chi P, Zhang Y, Lin H, Lu X, Huang Y . Survival outcome of adjuvant radiotherapy after local excision for T2 early rectal cancer: An analysis based on the surveillance, epidemiology, and end result registry database. Eur J Surg Oncol. 2018; 44(12):1865-1872. DOI: 10.1016/j.ejso.2018.08.024. View

13.

Han S, Pan Y, Yang X, Da M, Wei Q, Gao Y . Intestinal microorganisms involved in colorectal cancer complicated with dyslipidosis. Cancer Biol Ther. 2018; 20(1):81-89. PMC: 6343685. DOI: 10.1080/15384047.2018.1507255. View

14.

Emre A, Akbulut S, Sertkaya M, Bitiren M, Kale I, Bulbuloglu E . Assessment of risk factors affecting mortality in patients with colorectal cancer. Prz Gastroenterol. 2018; 13(2):109-117. PMC: 6040099. DOI: 10.5114/pg.2018.73348. View

15.

Reha J, Mukkamalla S, Rathore R, Somasundar P . Adequate lymph node evaluation in the elderly is associated with improved survival in patients with stage I-III colon cancer: A validation study using the National Cancer Data Base. Eur J Surg Oncol. 2017; 44(1):148-156. DOI: 10.1016/j.ejso.2017.11.005. View

16.

Brennan C, Garrett W . Fusobacterium nucleatum - symbiont, opportunist and oncobacterium. Nat Rev Microbiol. 2018; 17(3):156-166. PMC: 6589823. DOI: 10.1038/s41579-018-0129-6. View

17.

Sargent D, Marsoni S, Monges G, Thibodeau S, Labianca R, Hamilton S . Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010; 28(20):3219-26. PMC: 2903323. DOI: 10.1200/JCO.2009.27.1825. View

18.

Zheng Y, Luo Y, Lv Y, Huang C, Sheng Q, Zhao P . Clostridium difficile colonization in preoperative colorectal cancer patients. Oncotarget. 2017; 8(7):11877-11886. PMC: 5355311. DOI: 10.18632/oncotarget.14424. View

19.

Kelly D, Yang L, Pei Z . Gut Microbiota, Fusobacteria, and Colorectal Cancer. Diseases. 2018; 6(4). PMC: 6313651. DOI: 10.3390/diseases6040109. View

20.

Battaglin F, Naseem M, Lenz H, Salem M . Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. Clin Adv Hematol Oncol. 2018; 16(11):735-745. PMC: 7493692. View